Name layer
DMT usually means N,N-dimethyltryptamine: a tryptamine-family compound that SCM should keep distinct from 5-MeO-DMT, mebufotenin, psilocybin, ayahuasca preparations, and sponsor-specific drug programs.
The safest editorial move is to treat DMT as a compound page first. A source about DMT chemistry, endogenous detection, ayahuasca, or a specific clinical formulation does not automatically carry claims about every tryptamine page on the site.
Endogenous and botanical context
DMT appears in many discussions because it is both a naturally occurring compound and a modern research object. A peer-reviewed review in Frontiers in Neuroscience surveys the chemistry, pharmacology, and biological literature around DMT, while a Scientific Reports study detected DMT in rat brain extracellular fluid.
SCM should be conservative here: rat-brain detection and broad endogenous-DMT discussion are not evidence that DMT explains dreams, near-death experiences, mystical states, or any clinical outcome in humans. Those remain separate claims needing stronger sources.
Ayahuasca and route caution
DMT often enters public conversation through ayahuasca, but an ayahuasca brew is not the same evidence object as isolated DMT, inhaled DMT, intravenous DMT, or a regulated clinical protocol. Route, dose, preparation, setting, and legal jurisdiction all change what can be responsibly said.
When future SCM coverage adds ayahuasca, keep the tradition/preparation page separate from this compound page and avoid using either page as a generic substitute for the other.
Registry, legal, and company-source boundary
The source rail includes official/legal and program-boundary checks so this page is not only community- or review-sourced. eCFR is the federal legal-status anchor for the United States; ClinicalTrials.gov is the registry checkpoint for DMT-specific clinical-trial claims; GH Research is included as a company-boundary source because GH001 belongs to the 5-MeO-DMT lane, not this DMT dossier.
Those entries are boundary sources, not efficacy sources. A ClinicalTrials.gov search or a company pipeline page can show what is or is not being claimed in a program lane; they do not turn DMT into an approved treatment or make GH001 a DMT product.
SCM reading rule
Do not collapse the tryptamine family into one interchangeable bucket. DMT, 5-MeO-DMT, mebufotenin, and psilocybin should each carry their own source trail, evidence posture, legal posture, and program map.
Community references such as PsychonautWiki can help readers understand phenomenology and vocabulary, but they should never carry clinical, regulatory, or safety claims on their own.